Population-level analysis of cancer natural history, diagnostic pathways and outcomes across cancer types and ethnic groups in England

Data-sharing agreement from NHS England Data Uses Register. Evidence status: source reported.

Organisation: UNIVERSITY OF CAMBRIDGE
Published: 2026-09-14
Source reference: DARS-NIC-801407-W1X9R-v0.3
Jurisdiction: England
Licence: Open Government Licence v3.0, subject to NHS England terms and exclusions

Register reference: DARS-NIC-801407-W1X9R-v0.3
Applicant type: Academic
Data controllers: UNIVERSITY OF CAMBRIDGE
Agreement period: 2026-09-14 to 2029-09-13
For commercial purposes (as marked in the register): No
Release files listed by NHS England: 0

Data approved

NDRS Cancer Consolidated Data Set

Objective, as published

The Data will be used for the purpose of a research project: Population-level analysis of cancer natural history, diagnostic pathways and outcomes across cancer types and ethnic groups in England The research project aims to examine cancer incidence, diagnostic pathways, delays and outcomes across population groups, and to develop models (including breast cancer screening models) to assess impacts on mortality, inequalities and health service outcomes. The following are the aims/objectives of the processing: Workstream 1: Diagnostic delay across the 12 most common cancers • To understand cancer progression rates and quantify how diagnostic delay affects stage at diagnosis, mortality, and economic outcomes across the 12 most common cancers in England. • To identify cancer types and population groups where timely diagnosis has the greatest impact. • To develop cancer-type-specific multistate models using national cancer registry data. Workstream 2: Breast cancer natural history and screening evaluation • To develop ethnicity-specific models of breast cancer natural history and evaluate alternative screening strategies. The Data will be used to answer the following questions: 1) How does diagnostic delay influence the likelihood of being diagnosed with advanced-stage cancer and subsequent mortality across different cancer types? 2) How do cancer progression, outcomes, and the impact of delay vary by ethnicity, socioeconomic status, and other patient characteristi…

Expected benefits, as published

The findings of this research study are expected to contribute to evidence-based decision-making for policymakers, local decision-makers such as doctors, and patients to inform best practice to improve the care, treatment and experience of health care users relevant to the subject matter of the study. The use of the data could: Help the system to better understand the health and care needs of populations, particularly in relation to cancer progression, diagnostic delay, and outcomes across different cancers and population groups. Lead to improved understanding of how diagnostic delay affects stage at diagnosis and mortality, supporting earlier detection and better patient outcomes. Inform the design and refinement of diagnostic pathways and screening strategies, including evaluati…

Benefits reported by the applicant

Yielded Benefits is not a requirement for new applications.

This is the applicant's own account; OpenHDI has not verified it.

Source: https://digital.nhs.uk/services/data-access-request-service-dars/data-uses-register. Captured 2026-11-05.

Limitations: Data-sharing agreement as published in NHS England's Data Uses Register. An agreement permits access; actual data releases are listed separately. Expected and yielded benefits are as reported by the applicant and have not been independently verified. Long text fields can be cut off in NHS England's spreadsheet export at Excel's 32,767-character cell limit.